COVID-19 (Coronavirus) Update

A Phase Ib Study of Cobimetinib Administered In Combination with Niraparib, with or without Atezolizumab, to Patients with Advanced Platinum-Sensitive Ovarian Cancer

Protocol No
HOFFMANN-LAROCHE-YO40482
Principal Investigator
William Bradley
Phase
I
Summary
We want to find out more about the side effects (problems and symptoms) of a new drug for cobimentinib and how well it works in combination of other drugs.
Description
The purpose of this study is to evaluate the safety and efficacy of study drug cobimentinib given in combination with niraparib with or without atezolizumab in patients with platinum sensitive ovarian cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: